Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides-Reference-Cited by-同舟云学术

Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides

Published:2005-11-04 Issue:16 Volume:19 Page:1807-1818
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Dubé Michael P,Parker Robert A,Tebas Pablo,Grinspoon Steven K,Zackin Robert A,Robbins Gregory K,Roubenoff Ronenn,Shafer Robert W,Wininger David A,Meyer William A,Snyder Sally W,Mulligan Kathleen

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference46 articles.

1. Protease inhibitor-associated hyperglycaemia;Dubé;Lancet,1997

2. Severe diabetes associated with protease inhibitor therapy;Visnegarwala;Ann Intern Med,1997

3. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance due to HIV protease inhibitors;Carr;AIDS,1998

4. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients;Walli;AIDS,1998

5. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors;Behrens;AIDS,1999

Cited by 168 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dyslipidemia among adult people living with HIV on dolutegravir – based antiretroviral therapy at a private tertiary hospital in Kampala, Uganda: burden and determinants;BMC Infectious Diseases;2024-01-05

2. “We are Getting Those Old People Things.” Polypharmacy Management and Medication Adherence Among Adult HIV Patients with Multiple Comorbidities: A Qualitative Study;Patient Preference and Adherence;2022-10

3. Divergent effects of HIV reverse transcriptase inhibitors on pancreatic beta-cell function and survival: Potential role of oxidative stress and mitochondrial dysfunction;Life Sciences;2022-04

4. Management of hypercholesterolemia in individuals living with HIV/AIDS;Cholesterol;2022

5. Systematic analysis of safety profile for darunavir and its boosted agents using data mining in the FDA Adverse Event Reporting System database;Scientific Reports;2021-06-14